VA
VTGN icon

VR Adviser’s VistaGen Therapeutics VTGN Stock Holding History

VR Adviser’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-689,910
Closed -$18.2M – 33
2022
Q2 		$18.2M Buy
689,910
+155,000
+29% +$5.47M 3.59% 10
2022
Q1 		$19.9M Hold
534,910
– – 3.22% 13
2021
Q4 		$31.3M Hold
534,910
– – 4.28% 12
2021
Q3 		$44M Hold
534,910
– – 5.65% 5
2021
Q2 		$50.5M Sell
534,910
-8,510
-2% -$631K 6.13% 3
2021
Q1 		$34.7M Buy
543,420
+231,420
+74% +$15.4M 3.77% 10
2020
Q4 		$18.2M Buy
+312,000
New +$7.96M 2.67% 12

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VR Adviser's VTGN Position: Q3 2022 in Review

VR Adviser sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 689,910 shares — an estimated $18.2M sold.

VR Adviser first reported a position in VTGN in Q4 2020 and held it in 7 quarters. The position peaked at $50.5M in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • VR Adviser reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • VR Adviser sold 689,910 VistaGen Therapeutics shares in Q3 2022, an estimated $18.2M.
  • VR Adviser first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 7 quarters.
  • VR Adviser's VistaGen Therapeutics position peaked at $50.5M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on VR Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.